Recent data indicate that elevated circulating levels of FGF23 are independently associated multiple adverse cardiovascular outcomes in patients with chronic kidney disease (CKD) including vascular dysfunction16, left ventricular hypertrophy39, subclinical atherosclerosis, and mortality39–41. The gene discussed is FGF23; the disease is chronic kidney disease.